Press Releases

13 February 2023

Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM)

05 January 2023

Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC)

02 November 2022

Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences

07 September 2022

The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils, Halts Cancer Progression and Metastasis

03 August 2022

Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

01 June 2022

Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 April 2022

Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors

11 April 2022

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

10 March 2022

Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022

05 January 2022

Jubilant Therapeutics Announces FDA Clearance of IND for JBI-802, a Novel Dual LSD1 and HDAC6 Inhibitor, for treatment of Solid Tumors

10 November 2021

Jubilant Therapeutics Inc to participate and present at upcoming Investor Conferences

30 September 2021

Jubilant Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for its Novel Dual LSD1 and HDAC6 Inhibitor JB1-802

16 August 2021

Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. and Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMO

10 April 2021

Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021

08 March 2021

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

25 February 2021

Jubilant Therapeutics Announces Research Collaboration with Boston Children’s Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

05 February 2021

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors

15 January 2021

Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

07 December 2020

Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers

24 November 2020

Jubilant Therapeutics Announces Upcoming Presentation at 2020 ASH Virtual Annual Meeting

12 November 2020

Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology

04 November 2020

Jubilant Therapeutics to Participate in Upcoming Investor Conferences

20 October 2020

Jubilant Therapeutics Strengthens Scientific Advisory Board

22 June 2020

Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research, Reveals Unique Dual-Action Anti-Cancer Mechanism Underscoring First-in-Class Pipeline Asset in Hematological Tumors

What are you looking for?

News & Events